Leaflet DETRUSITOL SR 4mg prolonged release capsules


Indicated for: overactive bladder; urinary incontinence

Route of administration: oral

Substance: tolterodine (urinary antimuscarinic)

ATC: G04BD07 (Genito urinary system and sex hormones | Urologicals | Drugs for urinary frequency and incontinence)

Tolterodine is an antimuscarinic agent used in the treatment of overactive bladder, characterized by symptoms such as frequent urination, urinary urgency, and urinary incontinence. It works by blocking muscarinic receptors in the detrusor muscle of the bladder, reducing involuntary contractions and increasing bladder capacity.

Tolterodine is administered orally, usually once or twice daily, with the dose adjusted based on patient response and tolerability. It is available in immediate-release or extended-release tablet forms.

Common side effects include dry mouth, constipation, headache, and blurred vision. In rare cases, severe adverse reactions such as urinary retention or allergic reactions may occur. It is important for patients to follow the recommended dosage and inform their doctor of any side effects.

Tolterodine is an effective therapeutic option for managing overactive bladder symptoms, contributing to improved quality of life for patients.

General data about DETRUSITOL SR 4mg

  • Substance: tolterodine
  • Date of last drug list: 01-10-2014
  • Commercial code: W52804001
  • Concentration: 4mg
  • Pharmaceutical form: prolonged release capsules
  • Quantity: 28
  • Product type: original
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Pharmaceutical forms available for tolterodine

Concentrations available for tolterodine

  • 1mg
  • 2mg
  • 4mg